BTK and Hodgkins lymphoma: Seventeen percent (3 out of 18) of participants who received their third vaccine dose within 52 weeks of anti-CD20 administration demonstrated a rise in anti-S level in contrast with 75% (6 out of 8) of participants with B-NHL who were on concurrent BTK inhibitor or venetoclax therapy and 100% (3 out of 3) of patients with HL who were on chemotherapy (Fig. 6a and Supplementary Table 4a).